Prostatic Neoplasms, Castration-Resistant Withdrawn Phase Trials for Abiraterone (DB05812)

IndicationStatusPhase
DBCOND0001230 (Prostatic Neoplasms, Castration-Resistant)WithdrawnNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03325127Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study